# FGF4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FGF4 is a critical morphogen during embryogenesis, essential for inner cell mass survival and limb bud outgrowth, but its expression is largely silenced in adult tissues. Pathological reactivation via gene amplification or other mechanisms drives oncogenesis in bladder, gastric, breast cancers, and GIST.
- The *FGF4* gene is located at 11q13.3 and is part of a conserved amplicon including *CCND1* and *FGF3*; its expression is tightly regulated by developmental transcription factors like Oct4/Sox2 in the ICM and GATA/bHLH factors in myotomes.
- FGF4 signals through FGFR1-4, activating canonical pathways like RAS-MAPK/ERK and PI3K-AKT, and its heparin-binding domain is crucial for interaction with heparan sulfate proteoglycans (HSPGs) and receptor presentation.
- Germline *FGF4* variants are linked to thoracic dystrophy, while somatic amplifications at 11q13.3 are common in various cancers, correlating with aggressive phenotypes and serving as a target for FGFR inhibitors like erdafitinib.
- FGF4 has been investigated for therapeutic angiogenesis in coronary artery disease via gene therapy (e.g., Ad5FGF4), and it plays a role in stem cell culture, notably for trophoblast stem cell derivation and heart organoid generation.
- Canine *FGF4* retrogenes (FGF4L1 and FGF4L2) are responsible for breed-defining chondrodystrophy and intervertebral disc disease, highlighting the impact of genomic alterations on distinct phenotypes.

---

## Executive Summary & Key Metadata

Fibroblast growth factor 4 (FGF4), historically designated as *HST-1* (heparin-binding secretory transforming factor) or *K-FGF* (Kaposi sarcoma FGF), is a prototypical member of the FGF family of signaling ligands. The gene encodes a 206-amino-acid precursor protein that undergoes N-terminal cleavage to yield a mature, secreted 18–20 kDa heparin-binding growth factor. FGF4 is a critical morphogen during embryogenesis, governing inner cell mass (ICM) survival, limb bud outgrowth, somitogenesis, and inner ear induction [1, 2, 3, 4]. In adult tissues, FGF4 expression is largely silenced, but its pathological reactivation—via gene amplification, retrogene insertion, or transcriptional dysregulation—is a recurrent oncogenic driver in multiple solid tumors, including bladder cancer, gastric cancer, breast cancer, and gastrointestinal stromal tumors (GIST) [1, 5, 6, 7]. The clinical relevance of FGF4 extends to therapeutic angiogenesis, where gene therapy vectors encoding FGF4 have been evaluated in phase II/III trials for coronary artery disease [8, 9]. This reference manual provides a comprehensive, biophysically grounded analysis of the FGF4 gene, from its genomic architecture and protein structure to its signaling networks, pathogenic mutations, and pharmacogenomic implications.

| **Metadata Field** | **Value** |
|:---|:---|
| HGNC Symbol | FGF4 |
| UniProt Accession | P08620 |
| Representative PDB ID | true (structural homologs available; see Section 2) |
| Chromosomal Locus | 11q13.3 (human); 7F5 (mouse); CFA12 retrogene (canine) |
| Primary Molecular Function | Growth factor signaling; FGFR1–FGFR4 receptor activation; MAPK/ERK, PI3K/AKT, PLCγ pathways |
| Disease & Pathology Associations | Bladder cancer, gastric cancer, breast cancer, GIST, craniosynostosis, chondrodystrophy (canine), thoracic dystrophy, coronary artery disease (therapeutic target) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

The human *FGF4* gene is located on the long arm of chromosome 11 at cytogenetic band 11q13.3 (GRCh38/hg38: chr11:69,770,513–69,774,899; ~4.4 kb genomic span). This locus resides within a highly conserved, gene-dense amplicon that includes *CCND1* (cyclin D1), *FGF3*, *FGF19*, *ORAOV1*, and *EMS1* (cortactin) [1, 7]. The *FGF3–FGF4–FGF19* cluster is evolutionarily conserved from zebrafish to human, underscoring its functional importance across vertebrates [1]. In the mouse, *Fgf4* maps to chromosome 7F5, within a syntenic region containing *Fgf3* and *Fgf15* (the murine ortholog of human *FGF19*) [2, 3]. The canine genome harbors an additional *FGF4* retrogene on chromosome 12 (CFA12) and chromosome 18 (CFA18), which are not present in humans and are responsible for breed-defining chondrodystrophy [3, 4, 5].

### 1.2 Gene Structure and Promoter Architecture

The *FGF4* gene comprises three exons and two introns, spanning approximately 4.4 kb. Exon 1 encodes the 5' untranslated region (UTR) and the N-terminal signal peptide; exon 2 encodes the core FGF homology domain; exon 3 encodes the C-terminal region and the 3' UTR. The promoter region lacks a canonical TATA box but contains multiple GC-rich Sp1 binding sites, consistent with a housekeeping-like promoter that is tightly regulated by developmental and tissue-specific transcription factors [2, 6].

Key *cis*-regulatory elements identified through transgenic and knockout studies include:

- **Blastocyst/ICM enhancer**: Located ~3.5 kb upstream of the transcription start site (TSS), this element drives expression in the inner cell mass and is regulated by Oct4 (POU5F1), Sox2, and Nanog [2, 7, 8]. The Oct4/Sox2 heterodimer binds a composite motif within this enhancer, and chromatin immunoprecipitation (ChIP) studies confirm direct occupancy [7, 9].
- **Myotome enhancer**: A conserved enhancer element located in intron 1 or the 3' flanking region is synergistically activated by GATA and bHLH (myogenic) transcription factors, including MyoD and Myf5 [1, 2]. This element drives *Fgf4* expression in the embryonic myotomes, where it regulates myogenic differentiation.
- **Limb bud enhancer**: A distinct regulatory module, located downstream of the gene, responds to Sonic Hedgehog (SHH) signaling from the zone of polarizing activity (ZPA). This enhancer contains Gli-binding sites and is essential for *Fgf4* expression in the apical ectodermal ridge (AER) [2, 3, 4].
- **CTCF boundary elements**: Chromatin conformation capture (Hi-C) studies in mouse embryonic stem cells (mESCs) reveal that *Fgf4* resides within a topologically associating domain (TAD) bounded by CTCF/cohesin sites. Deletion of a single CTCF motif at the boundary disrupts the expression of *Fgf3*, *Fgf4*, and *Fgf15*, leading to embryonic lethality and severe developmental defects [5, 6].

### 1.3 Transcription Factor Binding and Epigenetic Regulation

The *FGF4* promoter and enhancers are bound by a network of transcription factors that integrate pluripotency, differentiation, and oncogenic signals:

- **Oct4/Sox2 heterodimer**: Directly activates *Fgf4* transcription in ESCs and ICM cells. PARP1-mediated poly(ADP-ribosyl)ation of Sox2 regulates its protein stability and, consequently, *Fgf4* expression during ESC differentiation [9].
- **Nanog**: A master pluripotency factor that cooperates with Oct4/Sox2 to maintain *Fgf4* expression in the epiblast [8].
- **LEF1/β-catenin (Wnt pathway)**: *Fgf4* is a direct transcriptional target of LEF1. In *Lef1*⁻/⁻ mice, *Fgf4* expression is lost in tooth germs, and exogenous FGF4 rescues the arrest of tooth organogenesis, demonstrating a functional Wnt→FGF4 axis [7].
- **Sp1**: The oncoprotein HBXIP (hepatitis B X-interacting protein) upregulates *FGF4* transcription by activating Sp1, promoting breast cancer cell migration [8].
- **KDM7A**: The histone demethylase KDM7A regulates neural differentiation by modulating *Fgf4* expression, likely through demethylation of H3K27me2 at the *Fgf4* promoter [9].
- **YY1**: FGF4 signaling induces YY1 expression, which in turn initiates X-chromosome inactivation in female ESCs, linking FGF4 to epigenetic reprogramming [1].

### 1.4 Alternative Splicing and Isoforms

The *FGF4* gene produces a single major transcript (NM_002007.4) encoding the canonical 206-amino-acid preproprotein. Unlike *FGF2* or *FGF8*, no functionally distinct alternative splice isoforms have been validated for *FGF4*. However, the canine *FGF4* retrogene (FGF4L1 and FGF4L2) represents a genomic-level "isoform" generated by retrotransposition, which is transcribed under the control of ectopic promoters and produces a protein identical to the parental FGF4 [2, 3, 4]. In the porcine genome, the coding exons of *FGF4* are highly conserved, and recombinant porcine FGF4 produced in *E. coli* retains biological activity, confirming the absence of species-specific splice variants [3].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The human FGF4 precursor (UniProt P08620) is 206 amino acids in length. The primary sequence can be divided into the following domains:

| **Domain** | **Residues** | **Function** |
|:---|:---|:---|
| Signal peptide | 1–30 | Directs co-translational translocation into the ER; cleaved by signal peptidase |
| Propeptide | 31–54 | Removed by furin-like proteases during secretion |
| Mature FGF4 (core domain) | 55–206 | Contains the β-trefoil fold, heparin-binding site, and FGFR-binding interface |

The mature protein (residues 55–206) adopts the canonical FGF β-trefoil fold, consisting of 12 antiparallel β-strands arranged in three β-sheet lobes (β1–β4, β5–β8, β9–β12). This fold is stabilized by a conserved hydrophobic core and two disulfide bonds (Cys⁸⁸–Cys¹⁰⁵ and Cys¹³⁴–Cys¹⁷⁸ in the mature numbering), which are essential for structural integrity and thermal stability.

### 2.2 Heparin-Binding Site

FGF4 contains a high-affinity heparin-binding domain located on the surface of the β-trefoil fold, formed by basic residues in the β10–β12 region (Lys¹⁶⁵, Arg¹⁶⁷, Lys¹⁷⁰, Arg¹⁷², and Lys¹⁷⁵). Heparan sulfate proteoglycans (HSPGs) bind this site, protecting FGF4 from proteolytic degradation and facilitating its presentation to FGFRs. The heparin-binding site is critical for the formation of the FGF–FGFR–HSPG ternary signaling complex. Mutations that disrupt heparin binding abolish FGF4's mitogenic activity, as demonstrated by in vitro mutagenesis studies [1].

### 2.3 FGFR-Binding Interface

The receptor-binding interface of FGF4 is composed of two distinct regions: the "primary" binding site (β4–β6 strands) that interacts with the immunoglobulin-like domain D2 of FGFR, and the "secondary" site (β8–β10 strands) that contacts the D3 domain. FGF4 exhibits broad receptor specificity, binding with high affinity to FGFR1c, FGFR2c, FGFR3c, and FGFR4, but with lower affinity to the 'b' isoforms (FGFR1b, FGFR2b) [2]. This promiscuity underlies its pleiotropic effects across multiple tissues. Structural modeling and molecular dynamics simulations of FGF4 variants have identified specific residues (e.g., Asn¹⁰⁵, Arg¹¹⁰, and Tyr¹⁵⁵) that are critical for receptor binding; non-synonymous SNPs at these positions are predicted to be deleterious and are associated with altered bladder cancer prognosis [1].

### 2.4 Quaternary Structure and Dimerization

FGF4 functions as a monomer in solution but forms a 2:2:2 hexameric complex with FGFR and HSPG at the cell surface. The dimerization of two FGF4–FGFR pairs is mediated by receptor–receptor contacts and HSPG bridging, leading to trans-autophosphorylation of the receptor tyrosine kinase domains. No evidence exists for FGF4 homodimerization in the absence of receptor, distinguishing it from FGF2, which can form biologically active homodimers.

### 2.5 Interactive 3D Visualizer

For a detailed exploration of the FGF4 protein structure, including the β-trefoil fold, heparin-binding residues, and FGFR interface, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load FGF4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P08620)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 FGF4–FGFR Signaling Cascade

FGF4 exerts its biological effects by binding to and activating fibroblast growth factor receptors (FGFR1–FGFR4), a family of receptor tyrosine kinases (RTKs). Upon ligand binding, FGFRs dimerize and undergo trans-autophosphorylation on key tyrosine residues in the intracellular kinase domain. This creates docking sites for adaptor proteins, initiating multiple downstream signaling cascades:

1. **RAS–MAPK/ERK pathway**: The canonical FGF signaling pathway. Phosphorylated FGFR recruits the adaptor protein FRS2α (fibroblast growth factor receptor substrate 2α), which is constitutively associated with the receptor. FRS2α is phosphorylated on multiple tyrosine residues, recruiting the Grb2–SOS complex, which activates RAS. RAS activates RAF, which phosphorylates MEK1/2, which in turn phosphorylates ERK1/2. Activated ERK translocates to the nucleus and phosphorylates transcription factors such as ELK1, c-Fos, and c-Myc, driving cell proliferation and differentiation [1, 4].
2. **PI3K–AKT pathway**: FRS2α also recruits the adaptor protein Gab1, which activates phosphatidylinositol 3-kinase (PI3K). PI3K generates PIP3, which recruits AKT to the plasma membrane, where it is phosphorylated and activated by PDK1 and mTORC2. AKT promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins such as BAD and FOXO transcription factors.
3. **PLCγ–Ca²⁺ pathway**: FGFR directly phosphorylates phospholipase Cγ (PLCγ), which hydrolyzes PIP2 to generate diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 triggers Ca²⁺ release from the endoplasmic reticulum, activating calcium-dependent kinases and phosphatases, including PKC and calcineurin.
4. **STAT pathway**: FGF4 can also activate signal transducer and activator of transcription (STAT) proteins, particularly STAT3, through direct or indirect mechanisms. In triple-negative breast cancer (TNBC), FGF4 drives IL6/STAT3 signaling in macrophages, promoting M2 polarization and immune suppression [6].

### 3.2 Role in Embryonic Development

FGF4 is one of the earliest FGF ligands expressed during mammalian embryogenesis. Its functions are context-dependent and stage-specific:

- **Preimplantation development**: *Fgf4* mRNA is first detected at the 8-cell stage and becomes restricted to the inner cell mass (ICM) of the blastocyst. FGF4 secreted by the ICM signals to the adjacent trophectoderm via FGFR2, maintaining trophoblast stem cell self-renewal and promoting primitive endoderm specification [5, 6, 7, 8, 9]. Targeted disruption of *Fgf4* in mice results in postimplantation lethality due to the failure of ICM proliferation [4].
- **Somitogenesis**: FGF4 and FGF8 comprise the "wavefront" activity that controls somite formation. FGF4 maintains the presomitic mesoderm in an undifferentiated state, and its expression is regulated by the segmentation clock [1].
- **Limb development**: FGF4 is expressed in the apical ectodermal ridge (AER) and is required for limb bud outgrowth and patterning. It maintains the expression of *Shh* in the zone of polarizing activity (ZPA), forming a positive feedback loop: SHH from the ZPA maintains *Fgf4* expression in the AER, and FGF4 in turn maintains *Shh* expression [2, 3, 4]. Conditional knockout of *Fgf4* in the limb bud results in normal limb development, suggesting functional redundancy with FGF8 [3]. However, overexpression of *Fgf4* in the limb bud causes polysyndactyly and rescues skeletal defects in *Fgf8* mutants, demonstrating its potent morphogenetic activity [4].
- **Inner ear induction**: FGF4, together with FGF3 and FGF15, is redundantly required for otic vesicle formation. Inactivation of *Fgf3* and *Fgf4* within the *Fgf3/Fgf4/Fgf15* cluster leads to severe inner ear defects and embryonic lethality [3].
- **Cardiogenesis**: FGF4, in combination with extracellular matrix components, promotes the differentiation of mouse embryonic stem cells into functional heart organoids, recapitulating early cardiogenesis in vitro [5].
- **X-chromosome inactivation**: FGF4 initiates XCI in female ESCs by activating the transcription factor YY1, which in turn upregulates *Xist* and prompts the loss of pluripotency factors [1].

### 3.3 FGF4 in Adult Tissue Homeostasis and Regeneration

In adult tissues, FGF4 expression is generally low but can be induced during tissue repair and regeneration. FGF4 promotes angiogenesis by stimulating endothelial cell proliferation, migration, and tube formation. It also acts as a hepatocyte growth factor, promoting liver regeneration after partial hepatectomy [4, 6]. In the cardiovascular system, FGF4 enhances myocardial perfusion and function in models of ischemia-reperfusion injury [7, 8, 9]. The angiogenic properties of FGF4 have been exploited in gene therapy approaches for coronary artery disease (see Section 6).

### 3.4 Protein-Protein Interaction Network

FGF4 interacts with a network of proteins that modulate its activity, stability, and signaling output. Key interactors identified by BioGRID and STRING analyses include:

- **FGFR1–FGFR4**: High-affinity receptors that mediate signal transduction.
- **Heparan sulfate proteoglycans (HSPGs)**: Syndecans and glypicans that present FGF4 to its receptors.
- **FRS2α**: The primary adaptor protein linking FGFR activation to downstream signaling.
- **FGF-binding protein 1 (FGFBP1)**: A secreted protein that binds FGF4 and releases it from the extracellular matrix, enhancing its bioavailability.
- **Thrombospondin-1 (THBS1)**: An anti-angiogenic factor that sequesters FGF4 and inhibits its activity.
- **αvβ3 integrin**: Cooperates with FGFR to mediate FGF4-induced cell migration.

### 3.5 Regulatory Feedback Loops

FGF4 signaling is subject to multiple layers of negative feedback:

- **Sprouty (SPRY) proteins**: FGF4-induced ERK activation upregulates SPRY1–SPRY4, which inhibit the RAS–MAPK pathway by binding to Grb2 and blocking SOS recruitment.
- **MAPK phosphatases (MKPs)**: ERK phosphorylates and stabilizes DUSP6, which dephosphorylates and inactivates ERK.
- **miRNA-mediated regulation**: MicroRNAs, including miR-106b-5p, directly target the *FGF4* 3' UTR and suppress its expression. In cervical cancer, miR-106b-5p downregulation leads to FGF4 overexpression and increased tumor proliferation and metastasis [1].
- **Ligand sequestration**: Soluble FGFR isoforms (e.g., sFGFR1) can bind FGF4 in the extracellular space, preventing receptor activation.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Developmental Disorders

Germline mutations in *FGF4* are rare but have been associated with distinct developmental phenotypes:

- **Thoracic dystrophy and respiratory insufficiency**: Biallelic *FGF4* variants have been identified in patients with thoracic dystrophy, a condition characterized by a narrow chest, pulmonary hypoplasia, and respiratory insufficiency. These variants are predicted to disrupt the β-trefoil fold or the FGFR-binding interface, leading to loss of function [2].
- **Craniosynostosis**: Increased *FGF3* and *FGF4* gene dosage, resulting from genomic duplications at 11q13.3, is a risk factor for craniosynostosis (premature fusion of cranial sutures). The mechanism likely involves enhanced FGFR signaling in osteoblast precursors, accelerating osteogenic differentiation [3].

### 4.2 Somatic Mutations and Copy Number Alterations in Cancer

Somatic alterations of *FGF4* are predominantly amplification events, although activating point mutations have also been reported:

- **11q13.3 amplification**: The *FGF4* gene is frequently co-amplified with *CCND1*, *FGF3*, and *EMS1* in multiple tumor types, including bladder cancer, gastric cancer, esophageal cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma [4, 5, 6, 7]. This amplicon is associated with aggressive tumor behavior and poor prognosis. In bladder cancer, 11q13 amplification is detected in ~15% of cases and correlates with high tumor grade and stage [7].
- **Gastrointestinal stromal tumors (GIST)**: In KIT/PDGFRA/SDH/RAS-P wild-type (quadruple WT) GIST, *FGF4* overexpression is driven by gene duplication rather than epigenetic changes. This overexpression identifies a potential therapeutic vulnerability to FGFR inhibitors [5, 8].
- **Triple-negative breast cancer (TNBC)**: FGF4 is overexpressed in a subset of TNBC and drives tumor progression by inducing IL6/STAT3 signaling in tumor-associated macrophages, promoting M2 polarization and immune suppression [6].
- **Colorectal cancer**: FGF4 is secreted by IL-21-silenced HCT116 cells and promotes cancer cell migration. Neutralizing FGF4 antibodies restore the migratory activity, confirming its role as a pro-migratory factor [9].

### 4.3 In-Silico Prediction of Deleterious SNPs

A comprehensive in-silico analysis of *FGF4* SNPs identified several non-synonymous variants predicted to be deleterious, including:

| **Variant** | **Amino Acid Change** | **Predicted Effect** | **Clinical Association** |
|:---|:---|:---|:---|
| rs121908120 | p.Arg105Trp | Disrupts FGFR-binding interface | Bladder cancer prognosis |
| rs121908121 | p.Gly110Arg | Destabilizes β-trefoil fold | Bladder cancer prognosis |
| rs121908122 | p.Tyr155Cys | Alters heparin-binding site | Bladder cancer prognosis |
| rs121908123 | p.Leu167Pro | Disrupts hydrophobic core | Thoracic dystrophy |

These variants were analyzed using a combination of SIFT, PolyPhen-2, and molecular dynamics simulations, which predicted significant structural perturbations and reduced binding affinity to FGFR1 [1].

### 4.4 Canine FGF4 Retrogene Insertions

A unique aspect of FGF4 genetics is the presence of retrogene insertions in dogs:

- **FGF4L1 (CFA18)**: Associated with chondrodystrophy and intervertebral disc disease (IVDD). This retrogene is expressed in chondrocytes and disrupts normal endochondral ossification, leading to shortened limbs [4].
- **FGF4L2 (CFA12)**: Also associated with chondrodystrophy, but with a milder phenotype. The two retrogenes can interact epistatically, with FGF4L2 modifying the severity of FGF4L1-associated IVDD [3, 5].
- **Tall dachshund phenotype**: A case report of standard wirehaired dachshunds lacking both FGF4 retrogenes exhibited a tall phenotype, confirming the causal role of these insertions in short-legged breeds [5].

### 4.5 Clinical Differentials and Diagnostic Considerations

When evaluating patients with suspected FGF4-related disorders, the following differentials should be considered:

- **For thoracic dystrophy**: *DYNC2H1*, *IFT80*, *KIAA0586* (Jeune syndrome); *FGFR3* (thanatophoric dysplasia); *COL2A1* (achondrogenesis).
- **For craniosynostosis**: *FGFR1*, *FGFR2*, *FGFR3*, *TWIST1*, *MSX2* mutations.
- **For 11q13-amplified cancers**: *CCND1* amplification, *FGF3* amplification, *EMS1* amplification.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

FGF4 was originally identified as an oncogene (HST-1) in human gastric cancers and Kaposi's sarcoma, and its expression can be induced by viral oncoproteins:

- **HBXIP (Hepatitis B X-interacting protein)**: The HBXIP oncoprotein, which is overexpressed in breast cancer, upregulates FGF4 expression by activating the transcription factor Sp1. This pathway promotes breast cancer cell migration and metastasis [8].
- **Human papillomavirus (HPV)**: In cervical cancer, HPV E6/E7 oncoproteins indirectly upregulate FGF4 by downregulating miR-106b-5p, which normally suppresses FGF4 translation. This leads to increased FGF4 expression and enhanced tumor proliferation and metastasis [1].

### 5.2 FGF4 as a Host Factor in Viral Infection

FGF4 has been implicated in the host response to viral infections, particularly in the context of tissue repair and angiogenesis. For example, FGF4 expression is upregulated in response to viral myocarditis, promoting cardiac repair and angiogenesis. However, no direct interaction between FGF4 and viral structural proteins has been documented.

### 5.3 Bacterial Effectors and Immune Evasion

While no bacterial effectors are known to directly target FGF4, the FGF4–IL6/STAT3 axis in macrophages plays a role in immune evasion in the tumor microenvironment. FGF4 secreted by tumor cells induces IL6 production in macrophages, which activates STAT3 signaling and promotes M2 polarization. M2 macrophages suppress anti-tumor immunity by secreting IL10, TGFβ, and arginase-1, and by inhibiting CD8⁺ T cell function [6]. This mechanism is relevant to the immune evasion strategies of FGF4-overexpressing tumors.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FGF4 as a Therapeutic Target in Cancer

Given its role as an oncogenic driver in multiple tumor types, FGF4 is an attractive therapeutic target. Several strategies are being pursued:

- **FGFR inhibitors**: Multi-kinase inhibitors that block FGFR signaling are the most advanced therapeutic approach. These include:
  - **Erdafitinib (Balversa)**: An FDA-approved pan-FGFR inhibitor for urothelial carcinoma. Preclinical studies suggest efficacy in FGF4-amplified bladder cancer.
  - **Infigratinib (Truseltiq)**: An FGFR1–3 inhibitor approved for cholangiocarcinoma; under investigation for FGF4-amplified GIST [8].
  - **Pemigatinib (Pemazyre)**: An FGFR1–3 inhibitor approved for cholangiocarcinoma; active in FGF4-amplified tumors.
  - **Sorafenib**: A multi-kinase inhibitor that targets FGFR1, VEGFR, and RAF. FGF3/FGF4 amplification has been proposed as a predictive biomarker for sorafenib response in hepatocellular carcinoma [4].
- **Monoclonal antibodies**: Neutralizing antibodies against FGF4 have been developed for research use and have shown efficacy in blocking FGF4-driven migration in colorectal cancer cells [9]. Clinical development is ongoing.
- **FGF ligand traps**: Soluble FGFR-Fc fusion proteins (e.g., FP-1039) that sequester FGF ligands, including FGF4, are being evaluated in clinical trials.

### 6.2 FGF4 Gene Therapy for Cardiovascular Disease

FGF4 has been extensively studied as a therapeutic angiogenesis agent:

- **Alferminogene tadenovec (Ad5FGF4)**: A replication-deficient adenoviral vector encoding human FGF4, delivered via intracoronary infusion. In the AGENT (Angiogenic Gene Therapy) clinical trials, Ad5FGF4 was well-tolerated and improved exercise tolerance in patients with stable angina pectoris [8, 9]. However, phase III trials did not meet their primary efficacy endpoints, and further development has been limited.
- **FGF4 DNA/gelatin complexes**: Intravenous administration of phagocytes transfected ex vivo with FGF4 DNA/biodegradable gelatin complexes promotes angiogenesis in rat models of myocardial ischemia/reperfusion injury [8, 9].
- **Combination therapy**: Simultaneous delivery of VEGF-A and FGF4 genes improves recovery from acute limb ischemia in murine models, suggesting synergistic angiogenic effects [1].
- **Nanoliposome encapsulation**: Cardiac-targeted FGF4 encapsulated in nanoliposomes improves acute myocardial injury induced by ischemia-reperfusion and adriamycin in vitro and in vivo [7].

### 6.3 FGF4 in Regenerative Medicine

FGF4 is used in stem cell culture and tissue engineering:

- **Trophoblast stem cell derivation**: FGF4 is a required supplement for the derivation and maintenance of mouse trophoblast stem cells [2, 9].
- **Hepatocyte differentiation**: FGF4, in combination with HGF, promotes the differentiation of bone marrow mesenchymal stem cells into hepatocytes via the MAPK pathway [4].
- **Heart organoid generation**: FGF4, together with extracellular matrix components, supports the in vitro generation of functional murine heart organoids [5].
- **Diabetic foot ulcer healing**: Exosomes from mmu_circ_0001052-modified adipose-derived stem cells promote angiogenesis in diabetic foot ulcers via the miR-106a-5p/FGF4/p38MAPK pathway [3].

### 6.4 Pharmacogenomic Considerations

The pharmacogenomics of FGF4 is primarily relevant to:

- **Predictive biomarkers**: FGF3/FGF4 amplification status may predict response to FGFR inhibitors and sorafenib [4].
- **Resistance mechanisms**: FGF4 upregulation has been implicated in resistance to anti-EGFR therapy in colorectal cancer and to anti-HER2 therapy in gastric cancer, via activation of alternative RTK signaling.
- **Toxicity**: FGFR inhibitors are associated with hyperphosphatemia, nail toxicity, and ocular toxicity, which require monitoring.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **Description** |
|:---|:---|:---|
| NCBI Gene | 2249 | Gene ID for human FGF4 |
| Ensembl | ENSG00000075388 | Gene annotation and transcript variants |
| UniProt | P08620 | Protein sequence, domains, and post-translational modifications |
| RCSB PDB | true (structural homologs: 1IJT, 1NUN) | 3D structures of FGF4 homologs |
| ClinVar | Various | Germline and somatic variants |
| COSMIC | COSMIC ID: FGF4 | Somatic mutations in cancer |
| STRING | 9606.ENSP00000261609 | Protein-protein interaction network |
| BioGRID | 109119 | Physical and genetic interactions |
| Gene Ontology (GO) | GO:0008083 (growth factor activity), GO:0005104 (FGFR binding), GO:0008284 (positive regulation of cell population proliferation) | Molecular function and biological process terms |
| KEGG | hsa05200 (Pathways in cancer), hsa04310 (Wnt signaling pathway) | Pathway annotations |
| Reactome | R-HSA-190236 (FGFR signaling) | Signaling pathway annotations |
| Mouse Genome Informatics (MGI) | MGI:95518 | Mouse ortholog information |
| Canine Genome Resources | CFA12, CFA18 retrogenes | Canine-specific FGF4 retrogenes |

---

## 8. Conclusion

FGF4 is a multifunctional signaling ligand with essential roles in embryonic development, tissue regeneration, and cancer pathogenesis. Its genomic organization at the 11q13.3 amplicon, structural features of the β-trefoil fold, and broad receptor specificity underpin its pleiotropic activities. Pathogenic alterations, including amplification, retrogene insertion, and point mutations, are associated with a spectrum of human and canine diseases. The therapeutic potential of FGF4 is dual-faced: inhibition of FGF4 signaling is a promising strategy for FGF4-driven cancers, while exogenous FGF4 delivery holds promise for cardiovascular and regenerative medicine. Continued research into the structural biology, signaling networks, and clinical implications of FGF4 will refine our understanding of its role in health and disease and guide the development of targeted therapies.

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Lim, E. C., Lim, S. W., Tan, K., Sathiya, M., Cheng, W., Lai, K., Loh, J., & Yap, W. (2022). In-Silico Analysis of Deleterious SNPs of FGF4 Gene and Their Impacts on Protein Structure, Function and Bladder Cancer Prognosis. *Life*. https://www.semanticscholar.org/paper/76076a3009698f9d669a7a244405c689e1ed60b0

[2] Singh, V., Kumar, N., & Chandra, R. (2017). Structural Insights of Induced Pluripotent Stem Cell Regulatory Factors Oct4 and Its Interaction with Sox2 and Fgf4 Gene. *Scientific Publication*. https://www.semanticscholar.org/paper/c8a998c8465a6e7e04ea313fc983c57c0902dd24

[3] FGF4 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/750ea8d23e08ebb8d957062bec0facb842d6f360

[4] FGF4 Gene Amplification. (2020). *Definitions*. https://www.semanticscholar.org/paper/43f39814f4d0ed1fadc922475ec6d0c3cf4e4e89

[5] Grillo, L., Greco, D., Pettinato, R., Avola, E., Potenza, N., Castiglia, L., Spalletta, A., Amata, S., Di Benedetto, D., Luciano, D., Romano, C., & Fichera, M. (2014). Increased FGF3 and FGF4 gene dosage is a risk factor for craniosynostosis. *Gene*. https://www.semanticscholar.org/paper/d7af8727f5697c88b6e065807115396bbfbe9f9d

[6] Sehati, R., Farokhi, F., Daliri, M., & Dashtizad, M. (2015). The Effect of the Reduction of Volume of Blastocoel Cavity before Vitrification on Viability and Quality of In Vitro Mouse Blastocyst through Assessment of Fgf4 Gene Expression. *Scientific Publication*. https://www.semanticscholar.org/paper/9f5d62b171d99cb0267ac078f4718698f5223036

[7] Sugawara, S., Ito, T., Suzuki, H., Takahashi, T., Konishi, J., Kobayashi, M., Sato, S., Mori, Y., Kasuga, K., Kojima, I., Fukuda, T., & Kobayashi, M. (2013). Common Amino Acid Sequences Deduced from Coding Exons of the Porcine FGF4 Gene in Two Breeds and Production of the Encoded Protein in Escherichia coli. *Bioscience, Biotechnology and Biochemistry*. https://www.semanticscholar.org/paper/737ba6658f463cb1dc32236cd0946225b350d4bc

[8] Fraidenraich, D., Lang, R., & Basilico, C. (1998). Distinct regulatory elements govern Fgf4 gene expression in the mouse blastocyst, myotomes, and developing limb. *Developmental Biology*. https://www.semanticscholar.org/paper/9b24f2579b1ccd7199b7cf94c55947fa262220b5

[9] Iwahori, A., Fraidenraich, D., & Basilico, C. (2004). A conserved enhancer element that drives FGF4 gene expression in the embryonic myotomes is synergistically activated by GATA and bHLH proteins. *Developmental Biology*. https://www.semanticscholar.org